BioSpace News Archive

CorMedix Inc. announced the pricing of its previously announced underwritten public offering of 7,500,000 shares of its common stock at a public offering price of $4.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 2,500,625 shares of its common stock at a price of $3.999 per pre-funded warrant.

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the Gibco™ OncoPro™ Tumoroid Culture Medium Kit *, the first commercially available culture medium specifically developed for the expansion of patient-derived tumoroids, or cancer organoids, from multiple cancer indications.

Alloy Therapeutics announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs optimally created spatial conformation nucleic acids that further enhance the drug-like properties of antisense.

Panbela Therapeutics, Inc today announced the SWOG Cancer Research Network’s PACES S0820 Phase III trial passed a single planned futility analysis and will continue.

OtoNexus Medical Technologies, a medical device innovator, is celebrating its recognition as one of Washington’s 100 Best Workplaces.

Sonnet BioTherapeutics Holdings, Inc. today announced that it has entered into a definitive agreement with a single institutional investor for the purchase and sale of an aggregate of 5,000,000 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $0.45 per share of common stock.

Amplifica Holdings Group, Inc. (“Amplifica”), a privately held, clinical-stage biopharmaceutical company announced the initiation of the first-in-human study of its lead candidate AMP-303.

Cerevance today announced plans to present a poster presentation at the upcoming XVI European Meeting on Glial Cells in Health and Disease, taking place in Berlin, Germany, July 8 – July 11, 2023.

Minerva Neurosciences, Inc. today announced that it has agreed to sell an aggregate of 1,425,000 shares of its common stock at a purchase price of $10 per share and pre-funded warrants to purchase an aggregate of 575,575 shares of its common stock at a purchase price of $9.99 per pre-funded warrant.

THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, announced the second investment of $5 million dollars in THINK Surgical by David Dvorak.